Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.
性状
Liquid
体外研究(In Vitro)
Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells.Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells.Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis
体内研究(In Vivo)
Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003). has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [2]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [3]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung car